{"sheets": {"分析サマリー": [["会社名", "G-ヘリオス"], ["コード", "4593"], ["表題", "業績予想の公表に関するお知らせ"], ["日付", "20260129"]], "財務データ一覧": [["勘定科目", "当期", "前期", "増減額", "増減率"], ["売上収益（IFRS）", null, 560000000, null, null], ["営業利益", null, -2843000000, null, null], ["税引前当期純利益", null, -4061000000, null, null], ["当期純利益", null, -4227000000, null, null], ["親会社株主に帰属する当期純利益", null, -4235000000, null, null], ["1株当たり当期純利益", null, -47.86, null, null], ["売上高", null, 571000000, null, null], ["経常利益", null, -2602000000, null, null], ["NetIncome", null, -2673000000, null, null], ["NetIncomePerShare", null, -30.21, null, null]], "XBRLデータ（Raw）": [["勘定科目", "XBRL要素名", "名前空間", "期間", "数値", "原文", "単位", "コンテキスト"], ["ReportingDateOfFinancialForecastCorrection", "ReportingDateOfFinancialForecastCorrection", "tse-ed-t", "当期末", null, "2026年1月29日", null, "CurrentYearInstant"], ["CompanyName", "CompanyName", "tse-ed-t", "当期末", null, "株式会社ヘリオス", null, "CurrentYearInstant"], ["TitleRepresentative", "TitleRepresentative", "tse-ed-t", "当期末", null, "代表執行役社長", null, "CurrentYearInstant"], ["NameRepresentative", "NameRepresentative", "tse-ed-t", "当期末", null, "鍵本　忠尚", null, "CurrentYearInstant"], ["SecuritiesCode", "SecuritiesCode", "tse-ed-t", "当期末", null, "45930", null, "CurrentYearInstant"], ["TitleInquiries", "TitleInquiries", "tse-ed-t", "当期末", null, "執行役CFO", null, "CurrentYearInstant"], ["NameInquiries", "NameInquiries", "tse-ed-t", "当期末", null, "リチャード・キンケイド", null, "CurrentYearInstant"], ["Tel", "Tel", "tse-ed-t", "当期末", null, "03-4590-8009", null, "CurrentYearInstant"], ["DocumentName", "DocumentName", "tse-ed-t", "当期末", null, "業績予想の公表に関するお知らせ", null, "CurrentYearInstant"], ["NoticeOfForecastCorrection", "NoticeOfForecastCorrection", "tse-ed-t", "当期末", null, "当社グループは、最近の業績の動向等を踏まえ、以下のとおり、2025年12月期（2025年１月１日～2025年12月31日）の業績予想を公表します。　なお、当社グループは、これまで連結業績予想及び単体業績予想を公表していなかったため、増減額及び増減率は前期実績に対する数値を記載しております。", null, "CurrentYearInstant"], ["売上収益（IFRS）", "Revenue", "tse-ed-t", "予想", 104000000, "104", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["営業利益", "OperatingIncome", "tse-ed-t", "予想", -3393000000, "3,393", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["税引前当期純利益", "IncomeBeforeIncomeTaxes", "tse-ed-t", "予想", -2179000000, "2,179", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["当期純利益", "ProfitLoss", "tse-ed-t", "予想", -2281000000, "2,281", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["親会社株主に帰属する当期純利益", "ProfitLossAttributableToOwnersOfParent", "tse-ed-t", "予想", -2270000000, "2,270", "JPY", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["1株当たり当期純利益", "EarningsPerShare", "tse-ed-t", "予想", -21.08, "21.08", "JPYPerShares", "CurrentYearDuration_ConsolidatedMember_CurrentMember_ForecastMember"], ["売上収益（IFRS）", "Revenue", "tse-ed-t", "前期", 560000000, "560", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["営業利益", "OperatingIncome", "tse-ed-t", "前期", -2843000000, "2,843", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["税引前当期純利益", "IncomeBeforeIncomeTaxes", "tse-ed-t", "前期", -4061000000, "4,061", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["当期純利益", "ProfitLoss", "tse-ed-t", "前期", -4227000000, "4,227", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["親会社株主に帰属する当期純利益", "ProfitLossAttributableToOwnersOfParent", "tse-ed-t", "前期", -4235000000, "4,235", "JPY", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["1株当たり当期純利益", "EarningsPerShare", "tse-ed-t", "前期", -47.86, "47.86", "JPYPerShares", "PriorYearDuration_ConsolidatedMember_CurrentMember_ResultMember"], ["売上高", "NetSales", "tse-ed-t", "予想", 704000000, "704", "JPY", "CurrentYearDuration_NonConsolidatedMember_CurrentMember_ForecastMember"], ["営業利益", "OperatingIncome", "tse-ed-t", "予想", -2321000000, "2,321", "JPY", "CurrentYearDuration_NonConsolidatedMember_CurrentMember_ForecastMember"], ["経常利益", "OrdinaryIncome", "tse-ed-t", "予想", -2418000000, "2,418", "JPY", "CurrentYearDuration_NonConsolidatedMember_CurrentMember_ForecastMember"], ["NetIncome", "NetIncome", "tse-ed-t", "予想", -2483000000, "2,483", "JPY", "CurrentYearDuration_NonConsolidatedMember_CurrentMember_ForecastMember"], ["NetIncomePerShare", "NetIncomePerShare", "tse-ed-t", "予想", -23.07, "23.07", "JPYPerShares", "CurrentYearDuration_NonConsolidatedMember_CurrentMember_ForecastMember"], ["売上高", "NetSales", "tse-ed-t", "前期", 571000000, "571", "JPY", "PriorYearDuration_NonConsolidatedMember_CurrentMember_ResultMember"], ["営業利益", "OperatingIncome", "tse-ed-t", "前期", -2446000000, "2,446", "JPY", "PriorYearDuration_NonConsolidatedMember_CurrentMember_ResultMember"], ["経常利益", "OrdinaryIncome", "tse-ed-t", "前期", -2602000000, "2,602", "JPY", "PriorYearDuration_NonConsolidatedMember_CurrentMember_ResultMember"], ["NetIncome", "NetIncome", "tse-ed-t", "前期", -2673000000, "2,673", "JPY", "PriorYearDuration_NonConsolidatedMember_CurrentMember_ResultMember"], ["NetIncomePerShare", "NetIncomePerShare", "tse-ed-t", "前期", -30.21, "30.21", "JPYPerShares", "PriorYearDuration_NonConsolidatedMember_CurrentMember_ResultMember"], ["ReasonForForecastCorrection", "ReasonForForecastCorrection", "tse-ed-t", "当期", null, "2025年12月期の売上収益は104百万円の見込みであり、主に前期に計上したRPE細胞製造方法等に関するライセンス契約に基づく一時金収入470百万円の影響がなくなったことにより、前期実績値と比較して減少しております。　研究開発費2,115百万円（前連結会計年度は1,960百万円）、販売費及び一般管理費1,227百万円（前連結会計年度は1,374百万円）を計上し、営業利益は△3,393百万円となる見込みであります。　また、金融収益1,363百万円（前連結会計年度は373百万円）、金融費用147百万円（前連結会計年度は1,589百万円）を計上し、税引前利益△2,179百万円、当期利益△2,281百万円、親会社の所有者に帰属する当期利益△2,270百万円となる見込みであります。　なお、金融収益1,363百万円は、主にSaisei ファンドにおける外部投資家持分への損益振替額923百万円（前連結会計年度は163百万円）、デリバティブ評価益390百万円（前連結会計年度はデリバティブ評価損1,446百万円を金融費用に計上）の計上によるものであります。　Saisei ファンドにおける外部投資家持分への損益振替額は、当社の連結子会社である Saisei Bioventures, L.P.及びSaisei Bioventures, L.P.から出資を受けている株式会社Akatsuki Therapeuticsの損益を Saisei Bioventures, L.P.に出資している当社以外のリミテッド・パートナーに対して振替計上しているものです。　デリバティブ評価益及びデリバティブ評価損は主に当社が発行しました第21回新株予約権、第22回新株予約権及び第26回新株予約権を当期末時点の公正価値で評価したことに伴い発生した評価損益であり、国際会計基準（IFRS）の規則に従い計上しております非現金損益項目です。　単体業績に関しましては、連結業績と同様の理由による売上高への影響があるものの、連結子会社である株式会社Akatsuki Therapeuticsからの受託研究収益の計上により前期実績値と比較して増加しております。また、これにより営業利益、経常利益及び当期純利益は前期実績値と比較していずれも増加する見込みであります。", null, "CurrentYearDuration"], ["FiscalYearEnd", "FiscalYearEnd", "tse-ed-t", "当期末", null, "2025-12-31", null, "CurrentYearInstant"]]}}